AVI Nabs $11.5M Defense Contract

Xconomy Seattle — 

AVI Biopharma, the Bothell, WA-based developer of RNA-based therapies, said today it has won an expanded $11.5 million contract from the U.S. Defense Department to develop its drug candidate for Junin virus infection. The new contract means AVI has received $45 million in combined contracts to develop treatments for Ebola, Marburg, and now Junin viral infections. AVI (NASDAQ: AVII) said the cash comes from the Defense Threat Reduction Agency’s Transformational Medical Technologies Initiative for a therapy called AVI-7012. Shares of AVI climbed 28 percent to $2.01 at 9:46 am Eastern time on the news.

By posting a comment, you agree to our terms and conditions.

Comments are closed.